Svar Life Science

July 6, 2023

Diagnostic Panel Updates & Scientific Highlights

This summer, we have updated our diagnostic panels for Autoimmune nodopathy and Myasthenia Gravis to the benefit of both doctors and patients. We also report on a new exciting paper on the incidence of Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome in Sweden.

Read more below or download the newsletter in Swedish in pdf format.

Download pdf (Swedish)

July 6, 2023

Diagnostic Panel Updates & Scientific Highlights

This summer, we have updated our diagnostic panels for Autoimmune nodopathy and Myasthenia Gravis to the benefit of both doctors and patients. We also report on a new exciting paper on the incidence of Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome in Sweden.

Read more below or download the newsletter in Swedish in pdf format.

Download pdf (Swedish)

Updates to our Myasthenia Gravis Panel

Wieslab has previously offered panels for antibody analysis in serum for suspected myasthenia gravis (MG). We have decided to make updates to this panel to conform to the 2020 consensus program for MG in Sweden.

Our enhanced panel for MG includes analysis of antibodies against:

  • Acetylcholine receptor (ACh-R)
  • Low-density lipoprotein receptor-related protein 4 (LRP4)
  • Muscle-specific tyrosine kinase (MuSK)
  • Titin
See the panel

New Paper on Autoimmune Encephalitis & Paraneoplastic Syndromes

In a new article, Sonja Kosek and colleagues present data collected in collaboration with, among others, Wieslab Diagnostic Services. The work focuses on the incidence of autoimmune encephalitis (AE) and paraneoplastic neuronal syndromes (PNS) in Sweden between 2015 and 2019. The authors found that the number of cases doubled over the time period, which they believe is due to increased sampling and awareness of these symptoms.

Read more

Autoimmune Nodopathy Panel Updates

Autoimmune nodopathies were previously considered a subgroup of chronic inflammatory demyelinating polyneuropathy (CIDP). Nowadays, they are a separate diagnosis according to the European Academy of Neurology.

We have updated our panels for autoimmune nodopathy with two new tests. Wieslab now offers the following panels:

  • Autoimmune nodopathy/CIDP - screen IgG
  • Autoimmune nodopathy/CIDP - extended analysis (IgG4)

These panels contain analysis of antibodies against Contactin-1, CASPR1, and Neurofascin-155 and 186. The extended panel also contains IgG4 subclass determination of NF155 and CNTN1 if these are IgG-positive.

The Western blot method previously used has been replaced by indirect fluorescence on transfected cells (IFA, CBA). IgG4 subclass determinations are performed using live cell-based assays (CBA). These changes mean that we can offer panels for autoimmune nodopathy with faster responses, which benefits both doctors and patients.

Autoimmune nodopathy Autoimmune nodopathy – extended